NCT06509087 The Combined Utility of Angio-CT and MRI in Managing Chronic Musculoskeletal Pain: a Prospective Study to Evaluate the Efficacy of Transarterial Microembolization
| NCT ID | NCT06509087 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tri-Service General Hospital |
| Condition | Chronic Musculoskeletal Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 60 participants |
| Start Date | 2024-07-25 |
| Primary Completion | 2025-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 60 participants in total. It began in 2024-07-25 with a primary completion date of 2025-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Transarterial microembolization (TAME) is a novel treatment option for chronic musculoskeletal pain, especially suitable for patients who have not responded to conservative treatment or are unsuitable for surgical procedures. This minimally invasive technique primarily targets abnormal neovascularization for embolization, relying heavily on precise information provided by various imaging techniques to ensure the effectiveness and safety of the treatment. This study aims to explore the application of integrating preoperative magnetic resonance imaging (MRI) evidence of patient pain and intraoperative high-resolution synchronous imaging information from fused computed tomography (CT) and angiography systems. This integration is intended to enhance preoperative planning, intraoperative guidance, and final treatment outcome assessment, focusing on its crucial contribution to treatment success. It is hoped that this approach will provide pain intervention physicians with reliable diagnostic tools and safe treatment methods, thereby improving treatment outcomes for patients with chronic musculoskeletal pain.
Eligibility Criteria
Inclusion Criteria: * Patients with chronic musculoskeletal shoulder or knee joint pain in our hospital, including degenerative knee arthritis, adhesive capsulitis of the shoulder, and those confirmed by physical examination or ultrasound-guided injection to have tendinopathy or ligamentopathy, who have failed drug therapy, rehabilitation, or injection treatments, with a duration of symptoms greater than three months, are the target population of this study. Exclusion Criteria: * Pregnancy, coagulation disorders, symptoms of relevant local infections or tumors, and patients allergic to contrast agents. Patients must have complete medical records; those who do not meet the inclusion criteria will be excluded.
Contact & Investigator
Yi-Chih Hsu, M.D.
PRINCIPAL INVESTIGATOR
Tri-Service General Hospital, National Defense Medical Center
Frequently Asked Questions
Who can join the NCT06509087 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, up to 80 Years, studying Chronic Musculoskeletal Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06509087 currently recruiting?
Yes, NCT06509087 is actively recruiting participants. Contact the research team at doc31578@gmail.com for enrollment information.
Where is the NCT06509087 trial being conducted?
This trial is being conducted at Taipei, Taiwan.
Who is sponsoring the NCT06509087 clinical trial?
NCT06509087 is sponsored by Tri-Service General Hospital. The principal investigator is Yi-Chih Hsu, M.D. at Tri-Service General Hospital, National Defense Medical Center. The trial plans to enroll 60 participants.